BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 21767952)

  • 1. Optimization of a pyrazole hit from FBDD into a novel series of indazoles as ketohexokinase inhibitors.
    Zhang X; Song F; Kuo GH; Xiang A; Gibbs AC; Abad MC; Sun W; Kuo LC; Sui Z
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4762-7. PubMed ID: 21767952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electron density guided fragment-based lead discovery of ketohexokinase inhibitors.
    Gibbs AC; Abad MC; Zhang X; Tounge BA; Lewandowski FA; Struble GT; Sun W; Sui Z; Kuo LC
    J Med Chem; 2010 Nov; 53(22):7979-91. PubMed ID: 21033679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of indazoles as inhibitors of Tpl2 kinase.
    Hu Y; Cole D; Denny RA; Anderson DR; Ipek M; Ni Y; Wang X; Thaisrivongs S; Chamberlain T; Hall JP; Liu J; Luong M; Lin LL; Telliez JB; Gopalsamy A
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4758-61. PubMed ID: 21742493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electron density guided fragment-based drug design--a lead generation example.
    Abad MC; Gibbs AC; Zhang X
    Methods Enzymol; 2011; 493():487-508. PubMed ID: 21371603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformationally restricted novel pyrazole derivatives: synthesis of 1,8-disubstituted 5,5-dimethyl-4,5-dihydro-1H-benzo[g]indazoles as a new class of PDE4 inhibitors.
    Reddy TS; Kumar KS; Meda CL; Kandale A; Rambabu D; Krishna GR; Hariprasad C; Rao VV; Venkataiah S; Reddy CM; Naidu A; Dubey PK; Parsa KV; Pal M
    Bioorg Med Chem Lett; 2012 May; 22(9):3248-55. PubMed ID: 22464134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors.
    Pastor RM; Burch JD; Magnuson S; Ortwine DF; Chen Y; De La Torre K; Ding X; Eigenbrot C; Johnson A; Liimatta M; Liu Y; Shia S; Wang X; Wu LC; Pei Z
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2448-52. PubMed ID: 24767842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases.
    McBride CM; Renhowe PA; Heise C; Jansen JM; Lapointe G; Ma S; PiƱeda R; Vora J; Wiesmann M; Shafer CM
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3595-9. PubMed ID: 16603352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel series of positive modulators of the AMPA receptor: discovery and structure based hit-to-lead studies.
    Jamieson C; Basten S; Campbell RA; Cumming IA; Gillen KJ; Gillespie J; Kazemier B; Kiczun M; Lamont Y; Lyons AJ; Maclean JK; Moir EM; Morrow JA; Papakosta M; Rankovic Z; Smith L
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5753-6. PubMed ID: 20805031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacterial translation inhibitors, 1-acylindazol-3-ols as anthranilic acid mimics.
    Stiff C; Graber DR; Thorarensen A; Wakefield BD; Marotti KR; Melchior EP; Sweeney MT; Han F; Rohrer DC; Zurenko GE; Romero DL
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6293-7. PubMed ID: 18951783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medicinal chemistry inspired fragment-based drug discovery.
    Lanter J; Zhang X; Sui Z
    Methods Enzymol; 2011; 493():421-45. PubMed ID: 21371600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-driven HtL: design and synthesis of novel aminoindazole inhibitors of c-Jun N-terminal kinase activity.
    Stocks MJ; Barber S; Ford R; Leroux F; St-Gallay S; Teague S; Xue Y
    Bioorg Med Chem Lett; 2005 Jul; 15(14):3459-62. PubMed ID: 15950471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The discovery of benzanilides as c-Met receptor tyrosine kinase inhibitors by a directed screening approach.
    Allen JV; Bardelle C; Blades K; Buttar D; Chapman L; Colclough N; Dossetter AG; Garner AP; Girdwood A; Lambert C; Leach AG; Law B; Major J; Plant H; Slater AM
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5224-9. PubMed ID: 21835616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2.
    Ledeboer MW; Pierce AC; Duffy JP; Gao H; Messersmith D; Salituro FG; Nanthakumar S; Come J; Zuccola HJ; Swenson L; Shlyakter D; Mahajan S; Hoock T; Fan B; Tsai WJ; Kolaczkowski E; Carrier S; Hogan JK; Zessis R; Pazhanisamy S; Bennani YL
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6529-33. PubMed ID: 19857967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based design, synthesis, and antimicrobial activity of indazole-derived SAH/MTA nucleosidase inhibitors.
    Li X; Chu S; Feher VA; Khalili M; Nie Z; Margosiak S; Nikulin V; Levin J; Sprankle KG; Tedder ME; Almassy R; Appelt K; Yager KM
    J Med Chem; 2003 Dec; 46(26):5663-73. PubMed ID: 14667220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and SAR of 2-arylbenzotriazoles and 2-arylindazoles as potential treatments for Duchenne muscular dystrophy.
    De Moor O; Dorgan CR; Johnson PD; Lambert AG; Lecci C; Maillol C; Nugent G; Poignant SD; Price PD; Pye RJ; Storer R; Tinsley JM; Vickers R; Well Rv; Wilkes FJ; Wilson FX; Wren SP; Wynne GM
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4828-31. PubMed ID: 21741236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining NMR and X-ray crystallography in fragment-based drug discovery: discovery of highly potent and selective BACE-1 inhibitors.
    Wyss DF; Wang YS; Eaton HL; Strickland C; Voigt JH; Zhu Z; Stamford AW
    Top Curr Chem; 2012; 317():83-114. PubMed ID: 21647837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, structure-activity relationship, and pharmacophore modeling studies of pyrazole-3-carbohydrazone derivatives as dipeptidyl peptidase IV inhibitors.
    Wu D; Jin F; Lu W; Zhu J; Li C; Wang W; Tang Y; Jiang H; Huang J; Liu G; Li J
    Chem Biol Drug Des; 2012 Jun; 79(6):897-906. PubMed ID: 22381062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
    Zhu GD; Gandhi VB; Gong J; Thomas S; Woods KW; Song X; Li T; Diebold RB; Luo Y; Liu X; Guan R; Klinghofer V; Johnson EF; Bouska J; Olson A; Marsh KC; Stoll VS; Mamo M; Polakowski J; Campbell TJ; Martin RL; Gintant GA; Penning TD; Li Q; Rosenberg SH; Giranda VL
    J Med Chem; 2007 Jun; 50(13):2990-3003. PubMed ID: 17523610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and SAR of novel pyrazole-based thioethers as cathepsin S inhibitors: part 1.
    Lee-Dutra A; Wiener DK; Arienti KL; Liu J; Mani N; Ameriks MK; Axe FU; Gebauer D; Desai PJ; Nguyen S; Randal M; Thurmond RL; Sun S; Karlsson L; Edwards JP; Jones TK; Grice CA
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2370-4. PubMed ID: 20153648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and hit-to-lead optimization of novel allosteric glucokinase activators.
    Lang M; Seifert MH; Wolf KK; Aschenbrenner A; Baumgartner R; Wieber T; Trentinaglia V; Blisse M; Tajima N; Yamashita T; Vitt D; Noda H
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5417-22. PubMed ID: 21813277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.